Other Species / Isoforms
  MAPKAPK5 (mouse)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K51-ac
TQERFALkILLDRPK
1 0
MAPKAPK5 (human) TQERFALKILLDRPK K51
MAPKAPK5 iso2 (human) TQERFALKILLDRPK K51
MAPKAPK5 (mouse) TQERFALkILLDRPK K51-ac
S93
VQFPHESSPRARLLI
1 0
MAPKAPK5 (human) VQFPHESsPRARLLI S93-p
MAPKAPK5 iso2 (human) VQFPHESSPRARLLI S93
MAPKAPK5 (mouse) VQFPHESSPRARLLI S93
S115-p
GELFHRIsQHRHFTE
Upstream
Downstream
2 0
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
  • protein stabilization
Effects on Biological Processes:
  • signaling pathway regulation
  • transcription, induced
Regulatory protein:
  • PKACA (mouse)
MAPKAPK5 (human) GELFHRIsQHRHFTE S115-p
MAPKAPK5 iso2 (human) GELFHRISQHRHFTE S115
MAPKAPK5 (mouse) GELFHRIsQHRHFTE S115-p
K123
QHRHFTEKQASQVTK
0 1
MAPKAPK5 (human) QHRHFTEkQASQVTK K123-ub
MAPKAPK5 iso2 (human) QHRHFTEKQASQVTK K123
MAPKAPK5 (mouse) QHRHFTEKQASQVTK K123
K166
NSLDAPVKLCDFGFA
0 1
MAPKAPK5 (human) NSLDAPVkLCDFGFA K166-ub
MAPKAPK5 iso2 (human) NSLDAPVKLCDFGFA K166
MAPKAPK5 (mouse) NSLDAPVKLCDFGFA K166
T182-p
VDQGDLMtPQFTPYY
Upstream
Downstream
6 101
Effects on Modified Protein
  • acetylation
  • enzymatic activity, induced
  • intracellular localization
  • phosphorylation
Putative in vivo kinases:
  • P38B (mouse)
Treatment
  • 2-deoxyglucose
  • acadesine
  • glucose_starvation
MAPKAPK5 (human) IDQGDLMtPQFtPyY T182-p
MAPKAPK5 iso2 (human) IDQGDLMTPQFTPYY T182
MAPKAPK5 (mouse) VDQGDLMtPQFTPYY T182-p
T186
DLMtPQFTPYYVAPQ
0 11
MAPKAPK5 (human) DLMtPQFtPyYVAPQ T186-p
MAPKAPK5 iso2 (human) DLMTPQFTPYYVAPQ T186
MAPKAPK5 (mouse) DLMtPQFTPYYVAPQ T186
Y188
MtPQFTPYYVAPQVL
0 1
MAPKAPK5 (human) MtPQFtPyYVAPQVL Y188-p
MAPKAPK5 iso2 (human) MTPQFTPYYVAPQVL Y188
MAPKAPK5 (mouse) MtPQFTPYYVAPQVL Y188
K205
QRRHQKEKSGIIPTs
0 1
MAPKAPK5 (human) QRRHQKEksGIIPTs K205-ub
MAPKAPK5 iso2 (human) QRRHQKEKSGIIPTS K205
MAPKAPK5 (mouse) QRRHQKEKSGIIPTs K205
S206
RRHQKEKSGIIPTsP
0 1
MAPKAPK5 (human) RRHQKEksGIIPTsP S206-p
MAPKAPK5 iso2 (human) RRHQKEKSGIIPTSP S206
MAPKAPK5 (mouse) RRHQKEKSGIIPTsP S206
S212-p
KSGIIPTsPTPYTYN
0 5
MAPKAPK5 (human) ksGIIPTsPtPYTYN S212-p
MAPKAPK5 iso2 (human) KSGIIPTSPTPYTYN S212
MAPKAPK5 (mouse) KSGIIPTsPTPYTYN S212-p
T214
GIIPTsPTPYTYNKS
0 1
MAPKAPK5 (human) GIIPTsPtPYTYNKS T214-p
MAPKAPK5 iso2 (human) GIIPTSPTPYTYNKS T214
MAPKAPK5 (mouse) GIIPTsPTPYTYNKS T214
K286
DVVRKLLKVKPEERL
0 1
MAPKAPK5 (human) DVVRKLLkVKPEERL K286-ub
MAPKAPK5 iso2 (human) DVVRKLLKVKPEERL K286
MAPKAPK5 (mouse) DVVRKLLKVKPEERL K286
S348
RIQDLKVSLKPLHsV
0 1
MAPKAPK5 (human) RIQDLKVsLKPLHsV S348-p
MAPKAPK5 iso2 (human) RIQDLKVSLKPLHSV S348
MAPKAPK5 (mouse) RIQDLKVSLKPLHsV S348
S354-p
VSLKPLHsVNNPILR
Upstream
0 10
Treatment
  • insulin
  • LY294002
MAPKAPK5 (human) VsLKPLHsVNNPILR S354-p
MAPKAPK5 iso2 (human) VSLKPLHSVNNPILR S354
MAPKAPK5 (mouse) VSLKPLHsVNNPILR S354-p
K364-ac
NPILRKRkLLGtKPK
1 0
MAPKAPK5 (human) NPILRKRKLLGtKPK K364
MAPKAPK5 iso2 (human) NPILRKRKLLGTKPK K364
MAPKAPK5 (mouse) NPILRKRkLLGtKPK K364-ac
T368-p
RKRkLLGtKPKDGIY
Upstream
0 7
Treatment
  • IL-33
MAPKAPK5 (human) RKRKLLGtKPKDSVY T368-p
MAPKAPK5 iso2 (human) RKRKLLGTKPKDSVY T368
MAPKAPK5 (mouse) RKRkLLGtKPKDGIY T368-p
P469
VIEEQTLPHEPQ___
0 2
MAPKAPK5 (human) VIEEQTTsHEsQ___ S469-p
MAPKAPK5 iso2 (human) VIEEQTTSHESQ___ S467
MAPKAPK5 (mouse) VIEEQTLPHEPQ___ P469
P472
EQTLPHEPQ______
0 11
MAPKAPK5 (human) EQTTsHEsQ______ S472-p
MAPKAPK5 iso2 (human) EQTTSHESQ______ S470
MAPKAPK5 (mouse) EQTLPHEPQ______ P472